Welcome to our dedicated page for RIGEL PHARMACEUTICALS SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction. As EVP and Chief Medical Officer, she disposed of 3,758 shares of common stock on February 10, 2026 through a tax-withholding arrangement at $34.62 per share.
After this transaction, she directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. The transaction was coded as a payment of tax liability by delivering securities, which is typically associated with equity compensation events rather than an open-market sale.
State Street Corporation, a Massachusetts-based financial institution, has disclosed a passive ownership stake in Rigel Pharmaceuticals, Inc. common stock. As of the event date of 12/31/2025, State Street beneficially owned 1,091,223 shares, representing 6% of Rigel’s outstanding common stock.
State Street reports no sole voting or dispositive power over the shares. It has shared voting power over 1,064,192 shares and shared dispositive power over 1,091,223 shares, held through affiliated investment adviser subsidiaries including SSGA Funds Management, Inc. The holdings are certified as being in the ordinary course of business and not for influencing control of Rigel.
Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock. On 02/02/2026, he disposed of 5,718 shares of Rigel common stock at $36.01 per share in a transaction coded "F." After this transaction, he beneficially owned 46,986 shares, held directly. A footnote explains that this balance includes 1,000 shares acquired under the issuer's stock purchase plan.
Rigel Pharmaceuticals executive Dean L. Schorno, EVP & Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 02/02/2026, 5,488 shares of common stock were disposed of in a transaction coded "F" at a price of $36.01 per share.
Following this transaction, Schorno beneficially owned 59,247 shares of Rigel common stock in direct ownership. This total includes 500 shares acquired under Rigel’s stock purchase plan, as noted in the filing’s footnote.
Rigel Pharmaceuticals executive Raymond J. Furey, EVP, GC, CCO & Corp Sec, reported a disposition of common stock. On February 2, 2026, he disposed of 3,968 shares of Rigel common stock at $36.01 per share, reported with transaction code F.
After this transaction, Furey directly beneficially owned 35,862 common shares, which the disclosure notes includes 1,000 shares acquired under Rigel’s stock purchase plan.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported multiple insider stock transactions. On January 26, 2026, he exercised employee stock options in two 40,000-share lots at $27.40 per share and reported related dispositions of 35,211 and 35,424 common shares at $37 per share.
On February 2, 2026, he reported an additional disposition of 14,110 common shares at $36.01 per share. After these transactions, he directly beneficially owned 235,709 Rigel common shares, including 1,000 shares acquired under the company’s stock purchase plan. All share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
Rigel Pharmaceuticals director receives new stock option grant. Director Michael Patrick Miller was awarded a stock option for 12,000 shares of Rigel common stock on February 1, 2026, with an exercise price of $34.86 per share. The option vests in equal monthly installments from February 1, 2026 until the annual meeting at which he is first scheduled to be considered for election by stockholders, conditioned on his continued service on the board.
Rigel Pharmaceuticals director Michael Patrick Miller reported his initial ownership of company securities. He directly holds 187 shares of common stock and a stock option for 625 shares at an exercise price of $16.05 per share, expiring on October 3, 2034.
Of this option, 375 shares are already vested. The remaining 250 option shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, giving a clear schedule for when he gains full option rights.
Rigel Pharmaceuticals, Inc. appointed Michael P. Miller to its board of directors effective February 1, 2026. He will serve in the director class whose term ends at the 2027 annual stockholders’ meeting and will also join the company’s Compensation Committee.
As a non-employee director, Mr. Miller will receive a yearly cash retainer of $50,000, plus an additional annual $10,000 retainer for Compensation Committee service, both pro-rated for partial service periods. He received an initial stock option grant to purchase 12,000 shares of common stock under Rigel’s 2018 Equity Incentive Plan.
After each annual stockholders’ meeting, he will automatically receive an annual option to purchase 3,000 shares of common stock and 2,500 restricted stock units, pro-rated for any year of partial service, so long as he continues to serve as a non-employee director. The company entered into its standard indemnification agreement with him and states that he is independent, has no disclosable related-party transactions, and no family relationships with the company’s directors or executive officers.
Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025. These estimates are based on currently available information and do not include all details needed for a complete picture of the company’s financial condition or operating results for that period.
The company also disclosed that it issued a press release titled “Rigel Provides Business Update and 2026 Outlook,” which is included as Exhibit 99.1. That release contains a broader business update and the company’s outlook for 2026, and is incorporated by reference into this report.